Sugi Predict

Sugi Predict / Compounds / SCHEMBL774705

SCHEMBL774705

SCHEMBL774705

O=C(Cl)[C@H]1CCCN1C(=O)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PREP P48147 3/20 0.64
▸ CTRB1 P17538 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.59
▸ KDM1A O60341 1/20 0.59
▸ RCOR1 Q9UKL0 1/20 0.59
▸ TSHR P16473 2/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ KLK7 P49862 1/20 0.58
▸ KLK5 Q9Y337 1/20 0.58
▸ KDM4E B2RXH2 1/20 0.58
▸ LMNA P02545 1/20 0.58
▸ GFER P55789 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ ALDH1A1 P00352 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205438 1.00 PREP (0.64) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL20519 1.00 PREP (0.64) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL27881364 0.96 PREP (0.60) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL7246634 0.92 PREP (0.56) PREPCTRB1NPSR1KDM1ARCOR1
SCHEMBL29553 0.89 PREP (0.67) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL475715 0.89 PREP (0.67) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL205223 0.89 PREP (0.67) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL29658848 0.89 PREP (0.67) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL3680610 0.88 PREP (0.65) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL7326760 0.88 FKBP1A (0.66) PREPCTRB1NPSR1TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4567035-A1 NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Nextgen Bioscience Co., Ltd. (KR) 2025-06-11 — — EP disclosed
US-20250170092-A1 (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF PHARMALA BIOTECH INC. (CA) 2025-05-29 — — US disclosed
US-12042478-B2 (R)-2-[(2H-1,3-benzodioxol-5-yl)methyl]pyrrolidine and processes for preparation, compositions and uses thereof PHARMALA BIOTECH (CA) 2024-07-23 — — US disclosed
US-20240051947-A1 (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF PHARMALA BIOTECH INC. (CA) 2024-02-15 — — US disclosed
WO-2024030000-A1 NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 넥스트젠바이오사이언스 2024-02-08 — — WO disclosed
US-20230122651-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2023-04-20 — — US disclosed
US-20210122709-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2021-04-29 — — US disclosed
US-20200055813-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. 2020-02-20 — — US disclosed
US-20190002398-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2019-01-03 — — US disclosed
US-9994614-B2 N-methyl-D-aspartate receptor modulators and methods of making and using same NAUREX, INC. (US) 2018-06-12 — — US disclosed
US-5498626-A Acylaminoindole derivatives as 5-ht1 agonists PFIZER INC. (US) 1996-03-12 — — US disclosed
EP-0635014-B1 INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS PFIZER LTD (GB) 1996-01-17 — — EP disclosed
WO-1995019978-A1 TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE LABORATOIRES GLAXO WELLCOME S.A. (FR) 1995-07-27 — — WO disclosed
EP-0635014-A1 INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS. PFIZER LTD (GB) 1995-01-25 — — EP disclosed
EP-0619805-A1 INDOLE DERIVATIVES PFIZER HOSPITAL PRODUCTS, INC. (US) 1994-10-19 — — EP disclosed
EP-0592438-A1 INDOLE DERIVATIVES. PFIZER (US) 1994-04-20 — — EP disclosed
WO-1993021177-A1 INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS PFIZER LIMITED (GB) 1993-10-28 — — WO disclosed
WO-1993011106-A1 INDOLE DERIVATIVES PFIZER, INC. (US) 1993-06-10 — — WO disclosed
WO-1992006973-A1 INDOLE DERIVATIVES PFIZER INC. (US) 1992-04-30 — — WO disclosed
US-4545942-A IMMUNOREGULATORS; ANTITUMOR AGENTS SANKYO COMPANY, LIMITED (JP) 1985-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055813-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS F7, TUBA1C, TUBA4A PREP 3584/4885CTRB1 1806/4885NPSR1 4173/4885
US-12042478-B2 (R)-2-[(2H-1,3-benzodioxol-5-yl)methyl]pyrrolidine and processes for preparation, compositions and uses thereof NR3C2, PAH, SRD5A1 PREP 1466/4885CTRB1 2060/4885NPSR1 120/4885
US-20240051947-A1 (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF NR3C2, PAH, SRD5A1 PREP 1466/4885CTRB1 2060/4885NPSR1 120/4885
US-20190002398-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS F7, TUBA1C, TUBA4A PREP 3584/4885CTRB1 1806/4885NPSR1 4173/4885
US-20230122651-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS F7, TUBA1C, TUBA4A PREP 3584/4885CTRB1 1806/4885NPSR1 4173/4885
US-20250170092-A1 (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE AND PROCESSES FOR PREPARATION, COMPOSITIONS AND USES THEREOF NR3C2, PAH, ADH1C PREP 1304/4885CTRB1 1935/4885NPSR1 121/4885
US-20210122709-A1 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS F7, TUBA1C, TUBA4A PREP 3584/4885CTRB1 1806/4885NPSR1 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.